Contribute Try STAT+ Today

SAN DIEGO — The benefit for patients treated by an experimental blood disease drug from Acceleron Pharma (XLRN) and licensed to Celgene (CELG) was further clarified and debated by experts Saturday at a press conference during the American Society of Hematology annual meeting.

The Acceleron drug, called luspatercept, is widely expected to secure approval late next year based on results from two separate Phase 3 clinical trials demonstrating statistically significant reductions in the need for blood transfusions. The patients enrolled in these two studies were diagnosed with myelodysplastic syndrome (MDS), a cancer-like disease of the bone marrow, and beta-thalassemia, a rare inherited disorder that reduces the production of oxygen-carrying hemoglobin.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Great content useful for all the candidates of Data Science training who want to kick start these career in Data Science training field.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy